409353-42-0 Usage
Uses
Used in Medicinal Chemistry:
3-(3-Formyl-2,5-dimethyl-pyrrol-1-yl)-benzoic acid is used as a building block for the synthesis of novel organic compounds, contributing to the development of new drugs with unique therapeutic properties.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-(3-Formyl-2,5-dimethyl-pyrrol-1-yl)-benzoic acid serves as a starting material for the discovery and design of innovative pharmaceutical agents. Its potential biological activities and unique structural features make it valuable for further studies and research to fully explore its properties and applications in drug development.
Further studies and research are essential to understand the full potential of 3-(3-Formyl-2,5-dimethyl-pyrrol-1-yl)-benzoic acid in various applications, including its role in the synthesis of new compounds and its potential as a therapeutic agent in the treatment of various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 409353-42-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,9,3,5 and 3 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 409353-42:
(8*4)+(7*0)+(6*9)+(5*3)+(4*5)+(3*3)+(2*4)+(1*2)=140
140 % 10 = 0
So 409353-42-0 is a valid CAS Registry Number.
409353-42-0Relevant articles and documents
Small molecule fusion inhibitors: Design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3- carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41
He, Xiao-Yang,Lu, Lu,Qiu, Jiayin,Zou, Peng,Yu, Fei,Jiang, Xing-Kai,Li, Lin,Jiang, Shibo,Liu, Shuwen,Xie, Lan
, p. 7539 - 7548 (2013/11/19)
By a scaffold elongation strategy, a series of (Z)-3-(5-(3-benzyl-4-oxo-2- thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2, 5-dimethylpyrroles and related derivatives with a linear multi-aromatic-ring skeleton were designed, synthesized, and evaluated in HIV-1 gp41 and cellular assays. Among them, the most active compounds, 12e, 12g, and 12k with a one-carbon linker (n = 1) between the rhodanine (C) and phenyl (D) rings, exhibited very promising inhibitory potency with IC50 values of 1.8-2.6 μM and EC50 values of 0.3-1.5 μM against gp41 6-HB formation and HIV-1 replication in MT-2 cells, respectively. Additionally, they were almost equally effective against both T20-sensitive and resistant strains. The related SAR studies and molecular modeling results provided potential for further developing a new class of non-peptide small molecular fusion inhibitors targeting the HIV-1 gp41.
